NSD1 and head and neck cancer: We first depleted NSD1 with specific shRNAs in FaDu, SCC35 (both are human head and neck cancer cell lines) cells, and HaCat (human immortalized, non-tumorigenic epithelial) cells, and selected knockdown clones using different shRNAs for each line that had > 50% depletion of NSD1 expression compared to parental cells or cells expressing control shRNA (Fig. 8).